Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis

The Lancet Respiratory Medicine

Volumn 5, Issue 3, 2017, Pages 159-161

  Sotgiu, Giovanni ^a   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) GGaslini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

BACTERIAL TRANSMISSION; DRUG EFFICACY; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; INCIDENCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SHORT COURSE THERAPY; CLINICAL PROTOCOL; EPIDEMIC;

ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; EPIDEMICS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85008162832     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30432-5     Document Type: Note

References (12)

1. 1 WHO treatment guidelines for drug-resistant tuberculosis. 2016 update, 2016, World Health Organization, Geneva http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en (accessed Nov 18, 2016).
2. 2 Van Deun, A, Maug, AK, Salim, MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182 (2010), 684–692.
3. 3 Diel, R, Vandeputte, J, de Vries, G, Stillo, J, Wanlin, M, Nienhaus, A, Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 43 (2014), 554–565.
4. 4 WHO. Global tuberculosis report 2016, 2016, World Health Organization, Geneva http://www.who.int/tb/publications/global_report/en/ (accessed Nov 18, 2016).
5. 5 Falzon, D, Gandhi, N, Migliori, GB, et al., for the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 42 (2013), 156–168.
6. 6 Migliori, GB, Sotgiu, G, Gandhi, NR, et al., for the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 42 (2013), 169–179.
7. 7 Kendall, EA, Fojo, AT, Dowdy, DW, Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respir Med, 2016 published online Dec 15. http://dx.doi.org/10.1016/S2213-2600(16)30423-4.
8. 8 Javaid A, Ahmad N, Shaheen Z, Khan AH. Applicability of World Health Organization's recommended new shorter regimen in an MDR-TB high burden country. Eur Respir J (in press).
9. 9 van der Werf M, Hollo V, Kodmon C, Dara M, Catchpole M. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J (in press).
10. 10 Sotgiu, G, Tiberi, S, D'Ambrosio, L, Centis, R, Zumla, A, Migliori, GB, WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 387 (2016), 2486–2487.
11. 11 Sotgiu, G, Tiberi, S, D'Ambrosio, L, et al., for the International Carbapenem Study Group. Faster for less, the new ‘shorter’ regimen for multidrug-resistant tuberculosis. Eur Respir J 48 (2016), 1503–1507.
12. 12 Muñoz-Torrico M, Caminero JA, Migliori GB, et al. Diabetes is associated with severe adverse events in multidrug-resistant tuberculosis. Arch Bronconeumol (in press).